Trial Number

050-20

Age range

neonates (up to 28 days of postnatal age)

Gender

Male or Female

Enrolling Patients

Yes

Seizures occur more often during the neonatal period than at any other time during life. Due to growing evidence that neonatal seizures contribute to an adverse neurodevelopmental outcome, physicians are increasingly focused on the diagnosis and treatment of this condition. The current available data from randomized, controlled studies to support the choice of anti-epileptic drug (AED) for this indication are limited, and there are currently no definite recommendations on the most suitable treatment. Thus, there is a need to investigate which AEDs should be used to treat neonatal seizures and their most appropriate dosages. Furthermore, although newer AEDs are efficacious for the treatment of seizures in adults and older children, limited progress has been made in the treatment of neonatal seizures. Therefore, clinical studies to assess the efficacy and safety of new treatment options in neonates are warranted. This is a multicenter, open-label, randomized, active comparator study to evaluate the efficacy, safety, and pharmacokinetics of lacosamide in neonates with repeated electroencephalographic neonatal seizures.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.